BioMarin's rare disease therapy shows no clinical benefit in Phase 3 test
Reynald Castaneda / endpoints - BioMarin’s enzyme replacement therapy for a rare genetic disorder called ENPP1 deficiency delivered mixed results in a late-stage study. Patients with the condition don't produce enough of the ENPP1 enzyme, which generates plasma inorganic pyrophosphate .…
AI Summary: BioMarin reported a Phase 3 trial that failed to show clinical benefit for a rare‑disease therapy, undermining prior optimism and clouding the drug’s development pathway. The mixed late‑stage results force a strategic reassessment, cooling investor expectations and leaving researchers and patients waiting for next steps or alternative approaches.
Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61
Related Stories
Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128
Insmed shelves Brinsupri in skin indication after mid‑stage flop / 7 wks
FDA again rejects Aldeyra’s dry‑eye drug for weak evidence / 2 months
First-in-human trial primes immune system to accept donor livers / 6 wks
Experimental therapy significantly reduces Parkinson’s toxic protein in early trial / 7 wks
Bristol Myers and Hengrui strike up to $15.2B global oncology pact / 16 days
Avalyn upsizes IPO to raise cash for lung drug trials / 29 days
Alfasigma pays $300M to GSK for linerixibat rights, expanding liver-disease portfolio / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Autism, Adolescent Health, Supply Chain, Product Recall and look for the RSS link.
StackHealth Time Machine